Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Piperacillin Sodium

FDA-approved product (injectable, injection), marketed as Piperacillin, Pipracil.

Registered studies
50+
Lab records
245
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Piperacillin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Appendicitis
  • Bacterial disease
  • Cellulitis
  • Diabetic foot
  • Endometritis
  • Pelvic Inflammatory Disease
  • Peritonitis
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Penicillins with extended spectrum
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01CA12

Repurposing investigation

Piperacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA92.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli16.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 12 lab records
  • E. coli: measured active in 10 of 42 lab records
  • K. pneumoniae: measured active in 30 of 191 lab records
Open Piperacillin Sodium in ChEMBL Registered studies below
Show the latest 150 of 245 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Piperacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics of Piperacillin and Meropenem in ICU Patients

    NCT05134298 · start 2019-11-01

    Registered record
    Registry ID
    NCT05134298
    Conditions
    Antibiotic Pharmacokinetics
    Interventions
    Piperacillin/tazobactam, Meropenem
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-11-01
    Completion
    2023-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Pharmacokinetics
    InterventionPiperacillin/tazobactam, Meropenem
    PhaseNot recorded
    Registry statusUnknown

  • Computer-based Dosage Calculation for Antibiotics

    NCT03036826 · start 2019-06

    Registered record
    Registry ID
    NCT03036826
    Conditions
    Acute Kidney Insufficiency; Anti-Infective Agent Toxicity
    Interventions
    Piperacillin/tazobactam; Meropenem
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2019-06
    Completion
    2021-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Insufficiency; Anti-Infective Agent Toxicity
    InterventionPiperacillin/tazobactam; Meropenem
    PhaseNot recorded
    Registry statusWithdrawn

  • PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

    NCT03671967 · start 2019-05-01

    Registered record
    Registry ID
    NCT03671967
    Conditions
    Beta Lactam Resistant Bacterial Infection; Enterobacteriaceae Infections; Bacteremia
    Interventions
    Piperacillin/tazobactam; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2019-05-01
    Completion
    2027-04-01
    Enrolment
    1,084

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBeta Lactam Resistant Bacterial Infection; Enterobacteriaceae Infections; Bacteremia
    InterventionPiperacillin/tazobactam; Meropenem
    PhasePhase 4
    Registry statusRecruiting

  • Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae

    NCT03891433 · start 2019-04-01

    Registered record
    Registry ID
    NCT03891433
    Conditions
    Urinary Tract Infections; Enterobacteriaceae Infections; Infection Due to ESBL Bacteria; Carbapenem; Escherichia Coli Infection; Klebsiella Pneumoniae Infection; Clinical Trial; Drug Resistance, Bacterial
    Interventions
    Meropenem; Ertapenem 1000 MG; Piperacillin, Tazobactam 4-0.5G Solution for Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Suspended
    Start
    2019-04-01
    Completion
    2026-04-01
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Enterobacteriaceae Infections; Infection Due to ESBL Bacteria; Carbapenem +4 more
    InterventionMeropenem; Ertapenem 1000 MG; Piperacillin, Tazobactam 4-0.5G Solution for Injection
    PhasePhase 4
    Registry statusSuspended

  • Comparison of Two Empirical Antimicrobial Therapies of Prosthetic Joint Infection

    NCT03850860 · start 2018-12-01

    Registered record
    Registry ID
    NCT03850860
    Conditions
    Bone and Joint Infection
    Interventions
    empirical antibiotherapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-12-01
    Completion
    2019-06-01
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone and Joint Infection
    Interventionempirical antibiotherapy
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia

    NCT03006679 · start 2018-08

    Registered record
    Registry ID
    NCT03006679
    Conditions
    Hospital-Acquired Bacterial Pneumonia; Ventilator-Associated Bacterial Pneumonia; Hospital-Acquired Pneumonia; Ventilator-Associated Pneumonia
    Interventions
    Meropenem-Vaborbactam; Piperacillin/Tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-08
    Completion
    2020-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital-Acquired Bacterial Pneumonia; Ventilator-Associated Bacterial Pneumonia; Hospital-Acquired Pneumonia; Ventilator-Associated Pneumonia
    InterventionMeropenem-Vaborbactam; Piperacillin/Tazobactam
    PhasePhase 3
    Registry statusWithdrawn

  • Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion

    NCT04895657 · start 2018-07-27

    Registered record
    Registry ID
    NCT04895657
    Conditions
    Gram-Negative Infections
    Interventions
    Piperacillin/Tazobactam Continuous infusion; Piperacillin/Tazobactam Intermittent infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-07-27
    Completion
    2020-01-26
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Negative Infections
    InterventionPiperacillin/Tazobactam Continuous infusion; Piperacillin/Tazobactam Intermittent infusion
    PhasePhase 4
    Registry statusCompleted

  • Target Attainment of TDM-guided Infusion of Piperacillin/Tazobactam and Cefepim in Critically Ill Patients

    NCT04530045 · start 2018-05-02

    Registered record
    Registry ID
    NCT04530045
    Conditions
    Critical Illness; Antibiotic Toxicity; Sepsis; Septic Shock
    Interventions
    dosage of concentration of piperacillin and cefepim
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-05-02
    Completion
    2019-11-02
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Antibiotic Toxicity; Sepsis; Septic Shock
    Interventiondosage of concentration of piperacillin and cefepim
    PhaseNot recorded
    Registry statusCompleted

  • Amplification and Selection of Antimicrobial Resistance in the Intestine II

    NCT03140826 · start 2018-01-30

    Registered record
    Registry ID
    NCT03140826
    Conditions
    Antibiotic Selection Pressure
    Interventions
    meropenem
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-01-30
    Completion
    2020-07-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotic Selection Pressure
    Interventionmeropenem
    PhaseNot recorded
    Registry statusCompleted

  • Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia

    NCT03108690 · start 2017-10-01

    Registered record
    Registry ID
    NCT03108690
    Conditions
    Bacteremia
    Interventions
    Continuous infusion of beta-lactam antibiotics .; Therapeutic drug monitoring of beta-lactam antibiotics.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2017-10-01
    Completion
    2023-03-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionContinuous infusion of beta-lactam antibiotics .; Therapeutic drug monitoring of beta-lactam antibiotics.
    PhasePhase 4
    Registry statusWithdrawn

  • Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis

    NCT03289351 · start 2017-05-22

    Registered record
    Registry ID
    NCT03289351
    Conditions
    Perforated Appendicitis; Postoperative Infection
    Interventions
    Piperacillin, Tazobactam Drug Combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-22
    Completion
    2023-11-07
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerforated Appendicitis; Postoperative Infection
    InterventionPiperacillin, Tazobactam Drug Combination
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis

    NCT03019965 · start 2017-02-01

    Registered record
    Registry ID
    NCT03019965
    Conditions
    Sepsis
    Interventions
    Intermittent Piperacillin/tazobactam; Continuous Piperacillin/tazobactam; Intermittent Imipenem; Extended Imipenem; Intermittent Meropenem; Extended Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-02-01
    Completion
    2020-01-30
    Enrolment
    426

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    InterventionIntermittent Piperacillin/tazobactam; Continuous Piperacillin/tazobactam; Intermittent Imipenem; Extended Imipenem +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Antibiotic Dosing in Patients on Intermittent Hemodialysis

    NCT03909698 · start 2016-09-15

    Registered record
    Registry ID
    NCT03909698
    Conditions
    Kidney Failure, Chronic; Antibiotics; Hemodialysis
    Interventions
    Blood and urine sampling
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-09-15
    Completion
    2022-03-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Failure, Chronic; Antibiotics; Hemodialysis
    InterventionBlood and urine sampling
    PhaseNot recorded
    Registry statusCompleted

  • Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

    NCT02732327 · start 2016-05-17

    Registered record
    Registry ID
    NCT02732327
    Conditions
    Neoplasms; Febrile Neutropenia
    Interventions
    CAZ-AVI; Vancomycin; Linezolid; Cefepime; Meropenem; Piperacillin/tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2016-05-17
    Completion
    2016-06-27
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms; Febrile Neutropenia
    InterventionCAZ-AVI; Vancomycin; Linezolid; Cefepime +2 more
    PhasePhase 2
    Registry statusTerminated

  • Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

    NCT02753946 · start 2016-04

    Registered record
    Registry ID
    NCT02753946
    Conditions
    Urinary Tract Infection Symptomatic; Acute Pyelonephritis; Urinary Tract Infection Complicated
    Interventions
    ZTI-01; Piperacillin-tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-04
    Completion
    2017-05-30
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infection Symptomatic; Acute Pyelonephritis; Urinary Tract Infection Complicated
    InterventionZTI-01; Piperacillin-tazobactam
    PhasePhase 2 / Phase 3
    Registry statusCompleted